(Q42848282)

8 November 2017

0 references

Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder (English)

1 reference

8 November 2017

Stephen R Kraus

1

1 reference

8 November 2017

José Luis Ruiz-Cerdá

2

1 reference

8 November 2017

Diane Martire

3

1 reference

8 November 2017

Joseph T Wang

4

1 reference

8 November 2017

Adrian S Wagg

5

1 reference

8 November 2017

language of work or name

English

0 references

publication date

25 October 2010

1 reference

8 November 2017

1 reference

8 November 2017

volume

76

1 reference

8 November 2017

issue

6

1 reference

8 November 2017

page(s)

1350-1357

1 reference

The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society

8 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.03.097

Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.03.097

Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.03.097

The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.03.097

Combined behavioral and drug therapy for urge incontinence in older women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.03.097

Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.03.097

Clinical Efficacy, Safety, and Tolerability of Once-Daily Fesoterodine in Subjects with Overactive Bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.03.097

Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.03.097

Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.03.097

Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.03.097

Evaluation of drug-drug interactions with fesoterodine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.03.097

Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.03.097

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.03.097

The current state of knowledge on age, sex, and their interactions on clinical pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.03.097

Overactive bladder syndrome in older people

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.03.097

Tolterodine: a safe and effective treatment for older patients with overactive bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.03.097

Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.03.097

Darifenacin treatment of patients ≥ 65 years with overactive bladder: results of a randomized, controlled, 12-week trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.03.097

Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.03.097

Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.03.097

Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.03.097

Changes in overactive bladder symptoms after discontinuation of successful 3-month treatment with an antimuscarinic agent: a prospective trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.03.097

Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.03.097

Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.03.097

10.1016/J.UROLOGY.2010.03.097

7 January 2021

Identifiers

DOI

1 reference

release_q35hlbvsf5fehjy3jhpbltak7q

8 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/q35hlbvsf5fehjy3jhpbltak7q

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference